BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell-based disorders characterized by ineffective hematopoiesis, increased genomic instability and a tendency to progress toward acute myeloid leukemia (AML). MDS and AML cells present genetic and epigenetic abnormalities and, due to the...

Full description

Bibliographic Details
Main Authors: Fernando Vieira Pericole, Mariana Lazarini, Luciana Bueno de Paiva, Adriana da Silva Santos Duarte, Karla Priscila Vieira Ferro, Fernanda Soares Niemann, Fernanda Marconi Roversi, Sara Teresinha Olalla Saad
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-01-01
Series:Frontiers in Oncology
Subjects:
myelodysplastic syndromes
acute myeloid leukemia
BET member of bromodomain-containing proteins
azacitidine
AZD6738
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00016/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00016/full

Similar Items